A 4H4-positive hybridoma cell line and a single-chain antibody, their preparation method and application

By preparing 4H4-positive hybridoma cell lines and constructing single-chain antibodies, the problem of insufficient adaptability of existing anti-PDCoV S CTD protein monoclonal antibodies has been solved, achieving efficient detection and low-cost large-scale production, and providing technical support for PDCoV prevention and control.

CN123107937APending Publication Date: 2026-11-17JIANGXI AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611312893.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-27
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing monoclonal antibodies against PDCoV S CTD protein have insufficient adaptability, making it difficult to meet the needs of efficient detection and the preparation of small molecule antibodies based on them.

Method used

Purified S-CTD protein truncated variants were used as immunogens to immunize Balb/C mice and fuse with myeloma cells. 4H4-positive hybridoma cell lines were screened, and monoclonal antibodies were prepared. The genes of the heavy chain variable region and light chain variable region were amplified by RT-PCR to construct single-chain antibodies. High-purity single-chain antibodies were obtained by prokaryotic expression and purification.

Benefits of technology

We obtained monoclonal antibodies and single-chain antibodies with high specificity and stability, which are suitable for a variety of detection methods, low in cost, and easy to scale up. This fills the gap in the research and application of specific single-chain antibodies for the CTD domain of the PDCoV S protein and provides the material basis and technical support for the prevention and control of PDCoV.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107937A_ABST
    Figure CN123107937A_ABST
Patent Text Reader

Abstract

This invention provides a 4H4-positive hybridoma cell line and a single-chain antibody, along with their preparation method and applications. First, using purified PDCoV S protein CTD domain as an immunogen, mice are immunized, and cell fusion screening yields a 4H4-positive hybridoma cell line that stably secretes monoclonal antibodies against the PDCoV S protein. Then, based on this hybridoma cell line, total RNA is extracted, and the heavy chain variable region and light chain variable region genes are amplified by RT-PCR. These genes are then linked using a flexible linker peptide to construct the full-length single-chain antibody gene, cloned into the prokaryotic expression vector pET-28a, transformed into BL21 competent cells, and after induction expression, separation, purification, and dialysis renaturation, a specific single-chain antibody against the PDCoV S protein CTD domain is obtained. The single-chain antibody of this invention exhibits excellent antigen-binding activity and can be widely used in the specific detection of PDCoV and the preparation of related diagnostic reagents.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of bioengineering technology, and in particular to a 4H4 positive hybridoma cell line and a single-chain antibody, as well as their preparation methods and applications. Background Technology

[0002] Porcine deltacoronavirus (PDCoV) is a recently discovered enteric pathogenic coronavirus in pigs that can cause diarrhea and dehydration, resulting in economic losses to the pig farming industry. The S protein (spik protein) of PDCoV is a structural protein on the viral surface, with neutralizing epitopes believed to be concentrated in its C-terminal domain (S-CTD). Monoclonal antibody technology and single-chain antibody (scFv) technology have been widely used in the detection and research of viral proteins. Single-chain antibodies are small recombinant antibody fragments composed of heavy chain variable regions and light chain variable regions linked by flexible linker peptides, and can be prepared using prokaryotic expression systems.

[0003] However, existing monoclonal antibodies against PDCoV S CTD protein have shortcomings in terms of production cost, stability, and compatibility, making it difficult to meet the needs of low-cost production, efficient detection, and the preparation of small molecule antibodies based on them. Summary of the Invention

[0004] The purpose of this invention is to provide a 4H4 positive hybridoma cell line, its preparation method, and its application, aiming to solve the problem that existing monoclonal antibodies against PDCoV S CTD protein have insufficient adaptability, making it difficult to meet the needs of efficient detection and the preparation of small molecule antibodies based on them.

[0005] In a first aspect, the present invention provides a 4H4 positive hybridoma cell line, the 4H4 positive hybridoma cell line having the accession number CCTCC NO:C2026111, the depositary institution being the China Center for Type Culture Collection, the deposit date being May 20, 2026, and the deposit address being Wuhan University.

[0006] Secondly, the present invention provides a method for preparing a 4H4-positive hybridoma cell line, used to prepare the 4H4-positive hybridoma cell line as described above, the preparation method comprising:

[0007] Balb / C mice were immunized four times using purified S-CTD protein truncated variants as immunogens and adjuvants.

[0008] Monitor the titer of anti-S-CTD protein antibody in mouse serum. Once the titer reaches the preset standard, aseptically obtain mouse spleen cells.

[0009] Mouse spleen cells were fused with myeloma cells, and 4H4-positive hybridoma cell lines were obtained through screening and clonal culture.

[0010] Secondly, the present invention provides an application of the 4H4-positive hybridoma cell line as described above in the preparation of a monoclonal antibody against PDCoV S CTD protein, wherein the monoclonal antibody is secreted by the 4H4-positive hybridoma cell line.

[0011] In some embodiments, the application includes:

[0012] The 4H4-positive hybridoma cell line was expanded and cultured, and the cell culture supernatant was collected. After separation and purification, monoclonal antibodies were obtained.

[0013] Thirdly, the present invention provides an application of the 4H4-positive hybridoma cell line as described above in the preparation of a single-chain antibody against PDCoV S CTD protein, wherein the single-chain antibody is constructed based on the heavy chain variable region and light chain variable region genes of the monoclonal antibody secreted by the 4H4-positive hybridoma cell line.

[0014] In some embodiments, the application includes:

[0015] Total RNA was extracted from 4H4-positive hybridoma cell lines and reverse transcribed to synthesize cDNA.

[0016] Using the cDNA as a template, the heavy chain variable region VH gene and the light chain variable region VL gene were amplified by RT-PCR.

[0017] A full-length single-chain antibody gene was constructed by linking the VH and VL genes with a flexible linker peptide.

[0018] The full-length gene of the single-chain antibody was cloned into a prokaryotic expression vector to construct a recombinant expression plasmid.

[0019] The recombinant expression plasmid was transformed into host cells, and the single-chain antibody was obtained by induction of expression, separation and purification, dialysis and refolding.

[0020] Fifthly, the present invention provides a single-chain antibody against PDCoV S CTD protein, the nucleotide sequence of which is shown in SEQ ID NO.1 and the amino acid sequence of which is shown in SEQ ID NO.2.

[0021] In a sixth aspect, the present invention provides the use of a single-chain antibody against PDCoV S CTD protein as described above in the preparation of a kit for detecting or diagnosing PDCoV.

[0022] Compared with the prior art, the present invention has the following advantages:

[0023] 1. This invention provides monoclonal and single-chain antibodies against the PDCoV S CTD protein. The single-chain antibody is reported for the first time both domestically and internationally, filling a gap in the research and application of specific single-chain antibodies targeting the CTD domain of the PDCoV S protein in existing technologies. The monoclonal antibody exhibits high specificity and stable secretion, allowing direct use in PDCoV-related detection and research. It also provides a reliable gene source for the construction of small-molecule single-chain antibodies, enriching the antibody toolkit for PDCoV prevention and control, and providing a material basis and technical support for S protein function research and prevention and control technology development.

[0024] 2. The monoclonal antibody and single-chain antibody preparation process of this invention is reasonable, simple to operate, cost-controllable, and easy to scale up. The monoclonal antibody preparation process is controllable. By using the S-CTD truncated variant as an immunogen and optimizing the immunization and screening process, highly specific positive hybridoma cell lines and antibodies can be stably obtained. Considering the characteristic of single-chain antibodies being expressed in inclusion body form in prokaryotic expression systems, the dialysis refolding and nickel column affinity chromatography purification processes have been optimized, enabling efficient acquisition of high-purity, high-activity soluble single-chain antibodies, solving the problems of high difficulty in preparing existing PDCoV-related antibodies and the difficulty in large-scale application.

[0025] 3. Both the monoclonal antibody and the single-chain antibody of this invention can specifically recognize the PDCoV S CTD protein, but each has its own advantages and strong complementarity. The monoclonal antibody can be used in various detection applications such as Western blot, IFA, and ELISA, but its production cost is relatively high, and hybridoma cells may exhibit a negative antibody secretion ability. The single-chain antibody is also suitable for detection applications such as ELISA and immunofluorescence. While the activity of prokaryotically expressed antibodies may be lower than that of eukaryotic expression systems, it is easier to produce on a large scale at low cost. The two complement each other in terms of cost and activity, allowing for flexible selection based on different detection needs and application scenarios.

[0026] 4. This invention verified the binding activity of the single-chain antibody to the S-CTD protein using a double-antibody sandwich ELISA assay, verified the specific recognition ability of the single-chain antibody for the S-CTD protein at the protein level using Western blotting, and visually verified the specific binding and targeting effect of the single-chain antibody to the S-CTD protein in PDCoV-infected cells at the cellular level using immunofluorescence (IFA). These multi-level experimental verifications comprehensively demonstrate that the single-chain antibody of this invention possesses good antigen-binding activity and specificity, and is practically feasible for application in rapid screening, laboratory diagnosis, and S protein function research for PDCoV infection. Attached Figure Description

[0027] Figure 1 This is a diagram showing the PCR amplification results of the PDCoV S CTD gene in Example 1 of this invention;

[0028] Figure 2 A in Figure 2 In the diagrams, B represents the bacterial PCR identification and double enzyme digestion identification of the PET-28a-PDCOV-S-CTD recombinant plasmid in Example 1 of this invention.

[0029] Figure 3 In the diagram, A represents protein electrophoresis images under different induction conditions. Figure 3 B in the image represents the PAGE images of the supernatant and precipitate after the expression bacteria were lysed at different temperatures.

[0030] Figure 4 In the figure, A represents the purification result of PDCoV S CTD protein in Example 1 of this invention. Figure 4 In the figure, B represents the results of Western Blot analysis;

[0031] Figure 5 A in Figure 5 In Example 2 of this invention, B represents the titer results of the third and fourth immunizations of Balb / C mice using PDCoV S CTD protein.

[0032] Figure 6 This is a graph showing the analysis results of serum antibody verification in Example 2 of the present invention;

[0033] Figure 7 This is a verification diagram of mouse serum antibody IFA in Example 2 of the present invention;

[0034] Figure 8 is a Western Blot analysis result of monoclonal antibodies after screening against PDCoV S CTD protein in Example 3 of the present invention;

[0035] Figure 9 This is a graph showing the results of indirect immunofluorescence specificity identification of the anti-PDCoV S CTD protein monoclonal antibody in Example 3 of the present invention;

[0036] Figure 10 This is a diagram showing the amplification results of the heavy and light chains of the single-chain antibody gene in Example 4 of the present invention;

[0037] Figure 11 This is a PCR amplification result of the full-length recombinant single-chain antibody gene spliced ​​from the VH gene, linker, and VL gene in Example 4.

[0038] Figure 12 This is a PAGE image of the process of expressing and purifying single-chain antibodies in Example 5;

[0039] Figure 13 A in Figure 13B in the figure represents the results of SDS-PAGE and Western Blot detection of the single-chain antibody after dialysis refolding of the purified 4H4 single-chain antibody, respectively;

[0040] Figure 14 This is a diagram showing the results of a double-antibody sandwich ELISA against the single-chain antibody against the porcine deltacoronavirus PDCoV S CTD protein 4H4 in Example 6;

[0041] Figure 15 This is an IFA result diagram of the detection of PDCoV S protein using a single-chain antibody in Example 6.

[0042] The following detailed description, in conjunction with the accompanying drawings, will further illustrate the present invention. Detailed Implementation

[0043] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Unless otherwise defined, the technical or scientific terms used herein should have the ordinary meaning understood by those skilled in the art. The terms "comprising" and similar expressions used herein mean that the element or object preceding the word covers the element or object listed after the word and its equivalents, but does not exclude other elements or objects.

[0044] The applicant discovered that, in the preparation of monoclonal antibodies in this invention, the PDCoV S protein CTD domain was chosen as the immunogen for several reasons: First, the full-length S protein has a complex structure with numerous glycosylation sites, resulting in low in vitro expression efficiency and difficulty in controlling purity. The truncated variant retains the core antigenic epitope and simplifies the structure, reducing expression difficulty and improving purity. Second, the neutralizing epitopes of the S protein are mainly concentrated in the S-CTD region, which is the dominant antigenic epitope region of the PDCoV S protein and the main region for inducing neutralizing antibody production. The truncated variant can precisely induce the production of specific neutralizing antibodies, reducing non-specific antibodies. Third, the truncated variant exposes the core epitope, making the immunogenicity more concentrated and improving the efficiency and quality of monoclonal antibody screening. Based on this, mice were immunized with purified PDCoV S CTD protein. After fusion of spleen cells and myeloma cells, screening of positive hybridoma cell lines, and antibody purification, a monoclonal antibody that specifically binds to the PDCoV S CTD protein was successfully obtained. Based on this, the corresponding single-chain antibody (scFv) was further prepared. Total RNA was extracted from hybridoma cells that secreted the specific monoclonal antibody, and the VH and VL genes were amplified by RT-PCR. The VH and VL genes were linked by a flexible linker peptide to construct the full-length scFv gene. After being inserted into the recombinant expression vector, it was transformed into Escherichia coli BL21(DE3) and positive bacteria were screened. After induction expression and affinity chromatography purification, high-purity and active scFv was obtained.

[0045] Furthermore, antibodies, as key tools for specifically recognizing viral antigens, play an irreplaceable role in the diagnosis, research, and prevention of PDCoV. Monoclonal antibodies that specifically bind to the PDCoV S CTD protein exhibit high specificity and stable secretion, providing a reliable gene source for the construction of small-molecule antibodies. Their derived single-chain antibodies (scFv) are small molecular fragments formed by the tandem formation of VH and VL, retaining the specificity and activity stability of monoclonal antibodies, and possessing advantages such as small molecular weight, strong penetrability, simple preparation, low cost, and low immunogenicity. Both have broad application prospects in the diagnosis and basic research of PDCoV, overcoming the shortcomings of existing PDCoV-related antibody preparation methods, such as cumbersome preparation and high cost, thus providing new means for PDCoV prevention and control.

[0046] To identify and prepare specific monoclonal antibodies and single-chain antibodies against the porcine deltacoronavirus (PDCoV) S protein, clarify their functional activities, and thus provide technical support and material basis for the rapid detection of PDCoV, research on its pathogenic mechanism, and the development of related prevention and control products, this invention discloses and develops a specific single-chain antibody against the PDCoV S protein. Specifically, this is achieved through a process of first preparing the specific monoclonal antibody, then constructing a prokaryotic vector for the single-chain antibody against the S protein, expressing and purifying the antibody, and verifying its activity. The detailed process is as follows:

[0047] (1) First, the PDCoV S CTD antigen protein was amplified, induced to express and purified to provide a qualified immunogen for subsequent monoclonal antibody preparation. The operation was as follows: Based on the PDCoV S CTD gene sequence, specific primers were designed. Using cDNA synthesized by reverse transcription of PDCoV genomic RNA as a template, the S-CTD gene fragment was amplified by PCR technology, which was consistent with the expected results. After amplification, the target gene was cloned into the prokaryotic expression vector pET-28a to construct the S-CTD protein recombinant expression plasmid. The plasmid was digested with enzymes and sequenced to verify that the sequence was correct, proving that pET-28a-S-CTD was successfully constructed. Subsequently, the recombinant plasmid was transformed into competent E. coli cells. After expression was induced by IPTG, the cells were collected and sonicated. Then, the S-CTD protein was purified by Ni column affinity chromatography to obtain S-CTD antigen protein with qualified purity. The purified antigen protein was stored in a -80℃ freezer for later use.

[0048] (2) Next, using the purified S-CTD antigen protein as an immunogen, mouse immunization and monoclonal antibody preparation and verification were carried out. The operation was as follows: healthy female BALB / c mice were selected and immunized by subcutaneous injection. The first immunization was emulsified with Freund's complete adjuvant, the subsequent booster immunization was emulsified with Freund's incomplete adjuvant, and the last immunization was a pure antigen intraperitoneal injection. BALB / c mice were immunized four times, with each immunization occurring every two weeks. Seven days after the last immunization, tail vein blood was collected from the mice, and the titer of anti-S-CTD protein antibodies in the serum was detected by indirect ELISA. Mice with qualified serum titers were selected. Subsequently, the mice with qualified titers were sacrificed, and their spleens were aseptically harvested. Spleen cells were fused with myeloma cells (SP2 / 0), and hybridoma cells were screened using HAT selective medium. Clonal culture was performed using limiting dilution to obtain monoclonal hybridoma cell lines. The obtained monoclonal hybridoma cell lines were validated by ELISA, and a positive hybridoma cell line (4H4) that specifically binds to the S-CTD protein was selected. This cell line can secrete anti-PDCoV S-CTD protein-specific monoclonal antibodies and was retained for future use.

[0049] (3) The above steps have successfully yielded secretory anti-PDCoV S To further obtain a specific antibody that can be efficiently expressed and easily applied, this study used a positive hybridoma cell line for CTD protein-specific monoclonal antibodies as a basis to construct a single-chain antibody. Specifically, this was achieved through the construction of the pET-28a prokaryotic vector plasmid, as follows: 4H4 hybridoma cells were lysed, and total RNA was extracted. This RNA was then used as a template for reverse transcription to synthesize cDNA. Using universal primers for the conserved regions of the porcine antibody heavy and light chains, the variable regions of the heavy chain (VH) and light chain (VL) were amplified separately using RT-PCR. After amplification, the qualified target genes were recovered and purified. Then, using overlap extension PCR, the purified VH and VL genes were spliced ​​together with a (Gly4Ser) flexible linker peptide to form the full-length recombinant single-chain antibody gene. Finally, the spliced ​​recombinant gene was cloned into the pET-28a prokaryotic expression vector to construct the recombinant expression plasmid pET-28a-VH-linker-VL. The plasmid was verified, and after confirming the correct sequence and successful construction, it was stored for future use.

[0050] (4) Next, the recombinant plasmid transformation, protein preparation and preservation were carried out as follows: pET-28a-VH-linker-VL recombinant plasmid was transformed into the pre-prepared E. coli competent cells BL21. After transformation, positive recombinant bacteria were screened out. Then, the positive recombinant bacteria were taken and inoculated into liquid culture medium containing the corresponding antibiotics. After shaking culture, the bacterial culture was placed under low temperature conditions and 1mM IPTG was added to induce the expression of single-chain antibody (the antibody is expressed in the form of inclusion bodies). After induction, the bacterial precipitate was collected by centrifugation, and lysis buffer was added to the precipitate. The inclusion bodies were released by sonication. Then, the inclusion bodies were purified by nickel column purification to obtain the purified VH-linker-VL antibody protein. After purification, the protein solution was put into a dialysis bag and dialyzed under low temperature conditions. After annealing, the qualified VH-linker-VL antibody protein was stored under suitable conditions for later use.

[0051] (5) Finally, the verification experiment of the single-chain antibody was carried out as follows: First, the indirect ELISA experiment was carried out. The prepared single-chain antibody VH-linker-VL protein and PDCoV S-CTD protein were taken. The binding specificity and antibody titer of the two were detected by the experiment to verify the antigen binding ability of the antibody. Then, the WB experiment was carried out. The target protein and the single-chain antibody were taken. The recognition effect of the antibody on the target protein was detected by the experiment to help confirm the antibody specificity. Finally, the IFA experiment was carried out. PDCoV infected cells and the single-chain antibody were taken. The binding localization of the single-chain antibody and the S-CTD protein in the cell was observed by the experiment to fully verify the specificity, activity and application feasibility of the single-chain antibody.

[0052] The following will provide specific examples for illustration:

[0053] Example 1: Recombinant expression of PDCoV S CTD protein

[0054] Based on the nucleotide sequence information of the corresponding strain of porcine deltacoronavirus (PDCoV), a pair of primers for amplifying the PDCoVS-CTD gene was designed and synthesized by Qingke Biotechnology Co., Ltd. The sequence of the upstream primer S1-CTD-F is shown in SEQ ID NO.3, specifically: 5'-CCAAGCTTTGAGGTGTATTGTGCCAGT-3', with HindIII as the restriction enzyme site; the sequence of the downstream primer S-CTD-R is shown in SEQ ID NO.4, specifically: 5'-CGGAATTCATGGATGGGTTCTACTCCGAC-3', with EcoRI as the restriction enzyme site.

[0055] The amplified PDCoV S CTD target gene is 1036 bp in length. The nucleotide sequence of the PDCoV S CTD gene is shown in SEQ ID NO. 5, specifically:

[0056]

[0057] First, PDCoV viral genomic RNA was extracted and reverse transcribed to synthesize cDNA. The full-length PDCoV S-CTD gene was amplified using primers S-CTD-F and S-CTD-R. The PCR product was detected, identified, and recovered by 1% agarose gel electrophoresis. The approximately 1036 bp PDCoV S-CTD gene was amplified by PCR. Figure 1 As can be seen, lane M is the DNA molecular weight standard, and lane 1 is the specific amplification product of the PDCoV S CTD gene, with a size of approximately 1036 bp, which is consistent with the expected results.

[0058] The pET-28a DNA vector and PCR product were digested with HindIII and EcoRI, then ligated with T4 ligase for 3 hours. The resulting cells were then transformed into E. coli BL21 competent cells, spread evenly on kanamycin-resistant solid agar plates, and incubated at 37°C for 16 hours. Single colonies were then picked and cultured by shaking. PCR was used to verify the correctness of the recombinant expression plasmid. Figure 2 As shown, the PDCoV S CTD gene, approximately 1036 bp in size, was amplified by PCR in lanes 1-6 of the bacterial culture. The double enzyme digestion product showed a band at the 1036 bp position in electrophoresis, indicating successful digestion and the fragment size met expectations. The plasmid, correctly identified by PCR, was sent to Qingke Biotechnology Co., Ltd. for sequencing identification. Sequencing results showed that the PDCoV S CTD recombinant expression vector was successfully constructed. The positive recombinant plasmid, correctly identified by sequencing, can be used for subsequent experiments related to the preparation of anti-PDCoV-S-CTD protein monoclonal antibodies.

[0059] The procedure for prokaryotic expression and purification of recombinant PDCoV S CTD protein is as follows:

[0060] The pET-28a-PDCoV-S-CTD BL21 bacteria, identified as positive, were inoculated into LB liquid medium (containing 50 μg / mL kanamycin) at a ratio of 1:100. The culture was shaken at 37°C and 220 rpm until the OD value reached 0.6-0.8. The bacterial cultures were then incubated at 16°C and 37°C, respectively. IPTG was added to a final concentration of 0.8 mM to induce expression for 16 h. The results of finding the optimal induction conditions are as follows... Figure 3 A and Figure 3 As shown in B, Figure 3 In the diagram, lane M represents the protein molecular weight standard, lane 1 is the uninduced control group, lane 2 is the 37℃ induction group, lane 3 is the 16℃ induction group, and lane 4 is the empty vector induction group. Figure 3In the diagram, lane M represents the protein molecular weight standard, lane 1 represents the supernatant protein expression level induced at 16℃, lane 3 represents the supernatant protein expression level induced at 37℃, and lane 4 represents the precipitated protein expression level induced at 37℃. After induction under optimal conditions, the bacterial culture was collected by centrifugation at 4000 rpm and 4℃ for 10 min. The bacterial precipitate was washed twice with pre-cooled PBS buffer, the supernatant was discarded, and the cells were resuspended in a lysis buffer containing protease inhibitors. The cells were then sonicated on ice (300W, 3s operation, 5s interval, total 20 min) until the culture became clear and transparent. The culture was then centrifuged at 12000 rpm for 20 min at 4℃, the supernatant was discarded, and the inclusion body precipitate was collected. The precipitate was washed three times with washing buffer (containing 2M urea) to remove impurities. SKL denaturing solution was added to the precipitate, and the mixture was vigorously stirred and incubated overnight at 4℃ to slowly dissolve the inclusion bodies and release the target protein. The dissolved protein solution was centrifuged at 12000 rpm for 15 min at 4 °C. The supernatant was collected, and 210 μL of 20% PGE4000 (to a final concentration of 0.2%), 420 μL of 50 mM (0.03 g / mL) oxidized glutathione (to a final concentration of 1 mM), and 420 μL of 100 mM (0.03 g / mL) reduced glutathione (to a final concentration of 2 mM) were added sequentially. The mixture was gently inverted and thoroughly mixed. The mixture was then dialyzed overnight at 4 °C using a gradient dialysis process. After annealing, the mixture was centrifuged at 12000 rpm for 10 min at 4 °C. The supernatant was then placed in dialysis buffer and dialyzed for 3 days (changing the dialysis buffer daily) to obtain purified PDCoV S CTD protein. SDS-PAGE results showed that the purified recombinant PDCoV S CTD protein expressed in prokaryotes was approximately 42 kDa. Figure 4 In the diagram, A and M represent the protein molecular weight standard, and lanes 1-5 represent the purified PDCoV SCTD protein. The PDCoV SCTD protein contains 1167 base pairs and encodes approximately 389 amino acids, with an expected protein size of 42-43 kDa. This result is consistent with the expected position of the protein band. Subsequent Western blotting was performed using an anti-His tag. Figure 4 In the diagram, lane M in lane B represents the protein molecular weight standard, lane 1 represents the empty vector pET-28a, and lane 2 represents the pET-28a-PDCoV-S-CTD. Figure 4 As shown in B, the band at lane 2 is around 42 kDa, which is consistent with the protein size after induction.

[0061] Example 2: Screening and preparation of monoclonal antibodies against PDCoV S CTD protein

[0062] The recombinant porcine deltacoronavirus PDCoV S CTD protein purified and prepared in Example 1 was used as an immunogen to immunize mice in order to prepare specific monoclonal antibodies.

[0063] First, 6-week-old female BALB / c mice were selected and immunized with recombinant PDCoV S CTD protein as the immunogen. For the first immunization, the recombinant PDCoV S CTD protein and Freund's complete adjuvant were thoroughly emulsified and mixed at a 1:1 volume ratio, and the mice were injected with 200 μg of antigen per mouse. Two weeks later, a first booster immunization was performed, in which the recombinant PDCoV S CTD protein and Freund's incomplete adjuvant were emulsified and mixed at a 1:1 volume ratio, and the mice were injected subcutaneously at multiple sites at a dose of 100 μg per mouse. Thereafter, the same method and dosage were repeated every two weeks for a total of three booster immunizations.

[0064] Based on the results of the third immunization Figure 5 From A in the data, we can see that the titer of mouse 1 can reach 1:2. 7 The titer of 2 in mice was low. Based on the results of the fourth immunization... Figure 5 From B, we can see that the titer of mouse 1 can reach 1:2. 10 The titer of 2 in mice reached 1:2. 7 The antibody titer reached the expected standard and showed a significant improvement compared to the third immunization. Blood was collected from the orbital rim of mice before each immunization. Serum was separated, and the titer of anti-PDCoV S CTD protein antibodies in the mouse serum was measured. Western blotting was used to verify the specific binding ability of the serum antibodies. Empty vector plasmid GFP-C2 and recombinant plasmid GFP-PDCOV-S-CTD were transfected into 293T cells. Cell samples were collected for electrophoresis after 36 hours. Mouse serum and GFP-tagged antibody were selected as primary antibodies, respectively. Figure 6 It was observed that the sample group using mouse serum as the primary antibody showed a clear band at 70 kDa in lane 2, consistent with the predicted protein size expressed by the constructed recombinant plasmid GFP-PDCOV-S-CTD. The sample group using the GFP-tagged antibody as the primary antibody also showed a clear band at 70 kDa in lane 2. This indicates that the serum antibody possesses specific binding ability. Furthermore, indirect immunofluorescence (IFA) is needed to further verify the specific binding ability of the serum antibody. Specifically, the empty vector plasmid GFP-C2 and the recombinant plasmid GFP-PDCOV-S-CTD were transfected into 293T cells, and cell samples were collected after 36 hours. Figure 7 It was observed that the red cells stained with PE dye overlapped with the green fluorescent region of GFP, indicating co-localization of the two markers within the cells. Spleens were aseptically harvested from immunized mice with adequate titers, and spleen cells were fused with mouse myeloma SP2 / 0 cells. Monoclonal antibody preparation and hybridoma cell screening culture were then performed routinely. Two weeks after fusion, positive hybridoma cells secreting specific antibodies against PDCoV S CTD protein were screened using an indirect ELISA method. The specific method is as follows:

[0065] (1) Coating: Dilute the recombinant PDCoV S CTD protein to 7.5 μg / mL with coating buffer, add 100 μL / well to a 96-well ELISA plate, and coat overnight at 4°C;

[0066] (2) Washing: Discard the coating solution and wash 3 times with PBST containing 0.05% Tween-20, letting it stand for 3 minutes each time;

[0067] (3) Blocking: 200 μL of 5% skim milk powder blocking solution per well, block at 37℃ for 2 h;

[0068] (4) Washing: Discard the blocking solution, wash 3 times with PBST, and let stand for 3 minutes each time;

[0069] (5) Add primary antibody: 100 μL of culture supernatant of hybridoma cells to be screened / well, set up negative control (unimmunized mouse serum) and blank control (culture medium only), and incubate at 37℃ for 1 h;

[0070] (6) Washing: Discard the liquid in the well, wash 5 times with PBST, and let stand for 3 minutes each time;

[0071] (7) Add secondary antibody: Dilute HRP-labeled goat anti-mouse IgG polyclonal antibody with blocking buffer, add 100 μL / well to the microplate, and incubate at 37°C for 1 h;

[0072] (8) Washing: Discard the secondary antibody solution, wash 5 times with PBST, and let stand for 3 min each time;

[0073] (9) Color development: Prepare 100 μL of TMB color development solution per well and develop the color at 37°C in the dark for 10-15 min;

[0074] (10) Termination and judgment: 50 μL of 2 mol / L H2SO4 stop solution per well, mix well and measure the OD value at 450 nm using an ELISA reader. The threshold is 2.1 times the OD value of the blank control. If the OD value of the well to be screened is greater than the threshold and the OD value of the negative control is less than the threshold, it is considered positive.

[0075] Example 3: Western Blot detection of anti-PDCoV S CTD protein monoclonal antibody and specific identification by indirect immunofluorescence method.

[0076] The supernatant of positive hybridoma cells that secrete specific antibodies against PDCoV S CTD protein, selected by indirect ELISA, was used as the primary antibody. The specific reactivity of this hybridoma cell line was detected by Western blotting (WB) and indirect immunofluorescence assay (IFA), respectively, to verify the recognition specificity and binding activity of the hybridoma cell line for PDCoV S CTD protein. The specific steps are as follows: Hybridoma cell supernatant...

[0077] 3.1 Western Blot detection of monoclonal antibodies, the specific steps are as follows:

[0078] PK1 cells were seeded in 6-well cell culture plates and inoculated with the virus. After 24 hours of inoculation, the cells were collected. Cell lysis buffer was added to the collected cells, followed by protein loading buffer. After thorough mixing, the mixture was boiled for 10 minutes to completely denature the proteins. An equal volume of the denatured total protein was then loaded for SDS-PAGE electrophoresis. After electrophoresis, the proteins on the gel were transferred to a PVDF membrane. Subsequent blocking, incubation, and color development were performed as follows:

[0079] (1) Sealing: 5% skim milk powder sealing solution, seal PVDF membrane at 37℃ for 2 hours;

[0080] (2) Washing: Wash the PVDF membrane three times with TBST containing 0.05% Tween-20, 10 minutes each time;

[0081] (3) Add primary antibody: Take the supernatant of the selected positive hybridoma cells as the primary antibody, dilute it with PBS at 1:500, and incubate it with PVDF membrane at room temperature for 4 hours;

[0082] (4) Washing: Wash the PVDF membrane three times with TBST containing 0.05% Tween-20, 10 minutes each time;

[0083] (5) Add secondary antibody: Dilute HRP-labeled goat anti-mouse polyclonal antibody (1:5000) with blocking buffer and incubate with PVDF membrane at room temperature for 1 hour;

[0084] (6) Washing: Wash the PVDF membrane three times with TBST containing 0.05% Tween-20, 10 minutes each time;

[0085] (7) Color development: The PVDF membrane is brought into contact with the prepared ECL color development solution, and the color is developed in the dark. The results are captured by the gel imaging system.

[0086] Figure 8 Lane 1 contains lysate of PDCoV-infected LLC-PK1 cells, and lane 2 contains lysate of uninfected cells. Figure 8 It can be seen that when the supernatant of 4H4 hybridoma cells is used as the primary antibody, a specific band appears at around 150kDa, indicating that PK1 cells express PDCoV S CTD protein that binds to the monoclonal antibody 4H4 after infection, proving that the antibody has specific binding ability.

[0087] 3.2. Monoclonal antibody indirect immunofluorescence assay (IFA), the specific steps are as follows:

[0088] (1) Cell preparation: PK1 cells were seeded in 24-well cell culture plates and PK1 cells were inoculated with PDCoV for 24 h before the experiment was carried out;

[0089] (2) Washing: Discard the culture medium and wash the cell smears three times with PBS buffer, 5 min each time;

[0090] (3) Fixation: Add 4% paraformaldehyde fixative and fix at room temperature for 15 min;

[0091] (4) Washing: Discard the fixative and wash the cells three times with PBS for 5 minutes each time;

[0092] (5) Permeabilization: Add 0.1% Triton X-100 permeabilization solution and permeate at room temperature for 30 min;

[0093] (6) Washing: After permeabilization, wash three times with PBS buffer, 5 min each time;

[0094] (7) Sealing: 5% skim milk powder sealing solution, sealed at 37℃ for 1 hour;

[0095] (8) Washing: Discard the blocking solution and wash the cells three times with PBS for 5 minutes each time;

[0096] (9) Add primary antibody: The hybridoma cell supernatant prepared in Example 2 was diluted with PBS at a ratio of 1:500, added to a 6-well plate, and incubated at 37°C for 1.5 hours;

[0097] (10) Washing: Discard the primary antibody solution and wash the cells three times with PBS for 5 minutes each time;

[0098] (11) Add secondary antibody: Dilute FITC-labeled goat anti-mouse IgG polyclonal antibody (1:1000) with PBS, add to 6-well plate, and incubate at 37°C in the dark for 1 hour;

[0099] (12) Washing: Discard the secondary antibody solution and wash the cells three times with PBS for 5 minutes each time;

[0100] (13) Nucleus staining: Add DAPI staining solution and incubate at room temperature in the dark for 5 minutes;

[0101] (14) Washing: Discard the DAPI staining solution and wash the cells twice with PBS for 5 minutes each time;

[0102] (15) Microscopic examination: Add a small amount of PBS to moisturize, observe and take images with a fluorescence microscope.

[0103] like Figure 9As shown, after PK1 cells were inoculated with PDCoV for 24 h, the cells were lysed and subjected to IFA. The supernatant of the selected hybridoma cells was used as the primary antibody, and the supernatant in the wells of cells without hybridoma growth was used as the negative control. The results showed that when the supernatant of 4H4 hybridoma cells was used as the primary antibody, some cells could be clearly seen to show red light and were in the same position as the blue cells stained by DAPI. This indicates that the monoclonal antibody can specifically bind to the target antigen.

[0104] Example 4: Amplification of the 4H4 single-chain antibody gene and construction of the pET-28a recombinant expression plasmid

[0105] First, the pET-28a prokaryotic vector plasmid was constructed as follows: Hybridoma cells secreting a specific monoclonal antibody against the PDCoV S CTD protein were collected, and their total RNA was extracted. After extraction, this RNA was used as a template for reverse transcription to synthesize cDNA. Then, the synthesized cDNA was taken and specific primers were added, such as... Figure 10 As shown, the heavy chain variable region (VH) and light chain variable region (VL) genes were amplified separately using RT-PCR. After amplification, the qualified target genes were recovered and purified. Then, overlap extension PCR was used to splice the purified VH gene and VL gene together using a flexible linker peptide, as shown. Figure 11 As shown, the full-length recombinant gene VH-linker-VL of the single-chain antibody was formed; finally, the assembled recombinant gene was cloned into the pET-28a prokaryotic expression vector to construct the recombinant expression plasmid. The plasmid was verified, and after confirming that the sequence was correct and the construction was successful, it was stored for later use.

[0106] Example 5: Transformation of single-stranded recombinant plasmids, bacterial cell-induced expression, and purification of inclusion bodies

[0107] 5.1 Recombinant plasmid transformation, protein preparation and preservation, the procedures are as follows:

[0108] First, the successfully constructed pET-28a-VH-linker-VL recombinant expression plasmid was transformed into pre-prepared *E. coli* competent cells using the heat shock method. Positive recombinant bacteria were screened after transformation. Then, 500 μL of the positive recombinant bacteria, including the empty vector and the successfully constructed bacterial sample, were inoculated into 200 mL of LB medium containing kanamycin and placed in a 16°C shaking incubator. The culture was shaken until the OD value reached 0.6-0.8. 1 mL of the bacterial culture containing the target gene was used as a control, and the remaining culture was treated with IPTG (final concentration 1 mM). If induction was successful, the bacterial culture was lysed to determine whether the expression was in inclusion bodies or supernatant. The results showed that the antibody was expressed in inclusion body form. After induction, the bacterial pellet was collected by centrifugation. Lysis buffer (300 mM NaCl (17.55 g) and 50 mM NaH2PO4 (7.8005 g) were added to the pellet, and the pH was adjusted to 8.0. Add lysozyme to a concentration of 0.2-0.4 mg / mL, incubate at 37°C for 2 hours, then add 5 mL of sonication buffer per 100 mL of bacterial culture. Add PMSF before sonication to a final concentration of 1 mM. Sonicate on ice until the bacterial cells are clear. Inclusion bodies are released by sonication and then purified using a nickel column chromatography method. The purification process involves the following steps:

[0109] (1) Column packing: After packing the Ni column, allow ethanol to flow down.

[0110] (2) Equilibration: Add 5 ml of lysis buffer to the column to equilibrate the column. After the column is drained, repeat the process twice, adding a total of 15 ml of lysis buffer for equilibration.

[0111] (3) Sample loading: Add the dissolved protein to the column tube and collect the eluent to make a protein sample.

[0112] (4) Washing: Add 5 mL of wash buffer to the column to wash away non-specifically adsorbed proteins. Collect the wash buffer to prepare a protein sample. After drying, repeat the process 5 times, using a total of 30 mL of wash buffer.

[0113] (5) Elution: Use 15 mL of Elution buffer to elute the target protein. Collect the eluent in a 2 mL EP tube and measure the protein concentration using a spectrophotometer.

[0114] Figure 12 Lanes 1-7 in the image represent uninduced whole cells, induced whole cells, induction supernatant, induction precipitate, nickel column flow-through buffer, nickel column wash buffer, and 4H4 purified protein, respectively. Figure 12As can be seen, lane 1 contains uninduced whole bacteria, lane 2 contains induced whole bacteria with the inducible protein appearing at 31 kDa, lane 3 contains the supernatant of the induced group with very low content of the target protein, lane 4 contains the precipitate of the induced group with the target protein present, indicating that the 4H4 protein is expressed in inclusion bodies, lanes 5 and 6 indicate the purification efficiency, and lane 7 shows a single clear band, i.e., the 4H4 protein. After obtaining the purified single-chain antibody, it was dialysis refolded. After refolding was complete, the qualified single-chain antibody was stored under suitable conditions for later use. Figure 13 In the diagram, lane M in lane A represents the protein molecular weight standard, and lanes 1-2 represent the protein after dialysis with 4H4. Figure 13 Lane M in section B contains protein molecular weight standards, and lane 1 contains 4H4 single-chain antibodies. Figure 13 As shown in A, the dialysis results revealed a single, clear 4H4 protein band at 31 kDa, indicating high protein purification efficiency and concentration. Figure 13 As shown in B, the WB results show a single, clear band at 31 kDa, which is in the same position as the SDS-page band, indicating successful prokaryotic expression of the 4H4 protein.

[0115] The obtained 4H4 single-chain antibody was sequenced, and its nucleotide sequence is shown in SEQ ID NO.1, as follows:

[0116] TTTGATTTCCAGCTTGGTCCCCCCTCCGAACGTGTACGGAACATGTGAAGCTTGAAAGCAGTAATAAACTCCCAGATCCTCAGCGTCCACTCTACTGATCTTGAGTGTGAAATCTGTCCCTGATCCACTGCCACTGAACCTGTCTGGGACCCCAGAAAATCGGTTGGAAACTTTGTAGATCAGGAGCTTTGGAGACTGGCCTGGTTTCTGCAGGTACCATTCTAAATAGGTGTTTCCATTACTATGGACAATACTCTGACTAGATCTGCAAGAGATGGAGGCTTGATCTCCAAGACTGACAGGCAGGGAGAGTGGAGTCTGTGTGATCACAATGTCCGAGCCGCCACCTCCAGAGCCACCTCCGCCTGAGGAGACTATGAGAGTGGTGCCTTGGCCCCAGTAGGCGTCGTAACCGAATCTTGTACAGTAATAGACGGCAGAGTCCTCAGATGTCAGGCTGCGGAGCTCCATGTAGGCTGTGCTGGAGGATTTGTCTGCAGTCAGTGTGGCCTTGTCCTTGAACTTCTGATTGTAGGCAGTATCACCAGTTTCAGGATCAATAGCTCCAATCCATTCCAGGCCATGCACAGGTGTCTGCTTCACCCAATGAAATTCATAGTCAGAAAATGTGTAGCCCGAAGCCTTGCAGGACAGCGTCACTGAAGCCCCAGGCCTCACCAGCTCAGCCCCTGACTCCTGCAGCTGGACCTGGGATCCGCGACCCATTTGCTGTCCACCAGTCATGCTAGCCATATGGCTGCCGCGCGGCACCAGGCCGCTGCTGTGATGATGATGATGATGGCTGCTGCCCAT.

[0117] The sequenced amino acid sequence of the 4H4 single-chain antibody is shown in SEQ ID NO. 2, specifically as follows:

[0118] Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro ArgGly Ser His Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Gly Ser Gln ValGln Leu Gln Glu Ser Gly Ala Glu Leu Val Arg Pro Gly Ala Ser Val Thr Leu SerCys Lys Ala Ser Gly Tyr Thr Phe Ser Asp Tyr Glu Phe His Trp Val Lys Gln ThrPro Val His Gly Leu Glu Trp Ile Gly Ala Ile Asp Pro Glu Thr Gly Asp Thr AlaTyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser ThrAla Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys ThrArg Phe Gly Tyr Asp Ala Tyr Trp Gly Gln Gly Thr Thr Leu Ile Val Ser Ser GlyGly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Ile Thr Gln Thr Pro Leu SerLeu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser IleVal His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln SerPro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg PheSer Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Asp Ala GluAsp Leu Gly Val Tyr Tyr Cys PheGln Ala Ser His Val Pro Tyr Thr Phe Gly GlyGly Thr Lys Leu Glu Ile Lys *.

[0119] Example 6: Identification of anti-PDCoV S CTD protein 4H4 single-chain antibody using double-antibody sandwich ELISA, Western Blot, and indirect immunofluorescence (IFA)

[0120] After separation, purification, and dialysis refolding, a high-purity single-chain antibody with its native conformation against PDCoV S CTD protein was successfully obtained. To systematically verify the specific binding activity and binding titer of this single-chain antibody to the target antigen, a double-antibody sandwich ELISA detection system was constructed using 4H4 single-chain antibody and PDCoV S CTD antigen as the core, combined with anti-PDCoV S CTD protein monoclonal antibody. This classic antigen-antibody specific binding detection method was used to quantitatively and qualitatively verify the in vitro binding activity of the single-chain antibody, laying the foundation for subsequent functional experiments. First, a verification experiment of the 4H4 single-chain antibody was conducted, the specific procedures of which are as follows:

[0121] 6.1 Single-chain antibody 4H4 double antibody sandwich ELISA assay:

[0122] (1) Coating: Dilute the 4H4 single-chain antibody protein with PBS to 2 μg / mL, 1 μg / mL and 0.5 μg / mL respectively, add 100 μL to each well and coat overnight at 4℃;

[0123] (2) Washing: After coating, discard the liquid in the wells, wash the microplate with PBST washing solution 3 times for 3 minutes each time, and pat dry any remaining liquid in the wells;

[0124] (3) Blocking: Add 150 μL of PBST blocking solution containing 5% skim milk powder to each well and block at 37℃ for 2 h;

[0125] (4) Washing: After the blocking is completed, discard the blocking solution, wash with PBST washing solution 3 times, 3 min each time, and pat dry;

[0126] (5) Antigen incubation: The PDCoV S-CTD antigen protein was diluted to a concentration of 10 μg / mL, 5 μg / mL, 2 μg / mL, 0.5 μg / mL, and 0.05 μg / mL. 100 μL of diluted S-CTD protein was added to each well. Negative control wells and blank control wells were set up and incubated at 37℃ for 2 h.

[0127] (6) Washing: After antigen incubation, wash 3 times with PBST washing solution for 3 minutes each time, and pat dry;

[0128] (7) Monoclonal antibody incubation: Add 100 μL of the monoclonal antibody extracted from the diluted hybridoma cell supernatant to each well and incubate overnight at 4°C;

[0129] (8) Washing: After the monoclonal antibody incubation is complete, wash 3 times with PBST washing solution for 3 minutes each time, and pat dry;

[0130] (9) Secondary antibody incubation: Add diluted HRP-labeled secondary antibody, 100 μL per well, and incubate at 37℃ for 1 h;

[0131] (10) Washing: After the secondary antibody incubation is completed, wash 5 times with PBST washing solution for 3 min each time, and pat dry;

[0132] (11) Color development: Add 100 μL of TMB color development solution to each well and develop the color at 37℃ in the dark for 15-20 min;

[0133] (12) Termination and detection: Add 50 μL of 2M H2SO4 stop solution to each well, shake to mix, and then measure the OD value of each well at a wavelength of 450 nm using an ELISA reader.

[0134] Depend on Figure 14 As can be seen, the three broken lines represent different concentrations (2 μg / ml, 1 μg / ml, 0.5 μg / ml) of 4H4 single-chain antibody. As the antigen concentration decreases, the OD values ​​of each curve decrease, indicating that the amount of antibody binding to the antigen decreases. The results show that when the antigen concentration is 0.05 μg / ml, even when the scFV concentration is as low as 0.5 μg / ml, a positive reaction can still be observed (P / N > 2.1).

[0135] The specific binding activity of the anti-PDCoV S CTD protein single-chain antibody to the target antigen has been preliminarily verified by the double-antibody sandwich ELISA assay. To further verify the specific recognition ability of the single-chain antibody to the PDCoV S CTD protein at the protein molecular level and eliminate interference from non-specific binding, this study continued with Western blotting (WB) experiments. By utilizing the protein separation characteristics of SDS-PAGE electrophoresis and the specific binding reaction of antigen-antibody, the specific binding bands of the single-chain antibody to the target protein were detected, further confirming the specific recognition ability of the single-chain antibody to the target protein.

[0136] 6.2 Single-chain antibody 4H4 IFA experiment:

[0137] (1) Cell inoculation: PDCoV was used to infect LLC-PK1 cells on cell crawling sheets;

[0138] (2) Washing: Discard the culture medium and wash the cell smears three times with PBS buffer, 5 min each time;

[0139] (3) Fixation: Add 4% paraformaldehyde fixative and fix at room temperature for 15 min;

[0140] (4) Washing: After fixation, wash three times with PBS buffer, 5 min each time;

[0141] (5) Permeation: Add 0.1% Triton X-100 permeation solution and permeate at room temperature for 30 min;

[0142] (6) Washing: After permeabilization, wash three times with PBS buffer, 5 min each time;

[0143] (7) Blocking: Add blocking solution containing 5% BSA and block at 37℃ for 30 min;

[0144] (8) Washing: After blocking, wash three times with PBS buffer, 5 min each time;

[0145] (9) Single-chain antibody incubation: Add diluted 4H4 single-chain antibody and incubate overnight at 4°C;

[0146] (10) Washing: After the single-chain antibody incubation is complete, wash three times with PBS buffer, 5 min each time;

[0147] (11) Primary antibody incubation: Add diluted mouse anti-his tag antibody and incubate at 37°C in the dark for 2 hours;

[0148] (12) Washing: After the primary antibody incubation is complete, wash three times with PBS buffer, 5 min each time;

[0149] (13) Secondary antibody incubation: Add diluted FITC goat anti-mouse IgG and incubate at 37°C in the dark for 2 hours;

[0150] (14) Staining: Add DAPI staining solution and stain at room temperature in the dark for 5 min;

[0151] (15) Washing: After staining, wash three times with PBS buffer, 2 min each time;

[0152] (16) Mounting and observation: Mount the slide with an anti-fluorescence quencher, observe and photograph it under a fluorescence microscope.

[0153] Figure 15 The left-hand negative control group consisted of uninfected LLC-PK1 cells, which were sequentially incubated with 4H4 single-chain antibody and mouse anti-His antibody. The middle control group consisted of infected LLC-PK1 cells, which were then incubated with mouse anti-His antibody. The right-hand positive group consisted of infected LLC-PK1 cells, which were sequentially incubated with 4H4 single-chain antibody and mouse anti-His antibody as the primary antibody. They were then incubated with goat anti-mouse FITC-fluorescent secondary antibody. Figure 15It can be seen that the goat anti-mouse FITC-fluorescent secondary antibody used in the 4H4 single-chain antibody experimental group can be accurately labeled on the corresponding cells, showing obvious green fluorescence, and is in the same position as the blue cells stained by DAPI dye. This indicates that the scFV can specifically bind to the target antigen.

[0154] In summary, the above embodiments first introduce the preparation of monoclonal antibodies against PDCoV S protein. The monoclonal antibody uses the purified PDCoV S protein CTD domain as an immunogen, and is combined with adjuvants to immunize experimental mice in multiple rounds. The antibody titer of mouse serum is continuously monitored. After the titer reaches the target, mouse spleen cells are fused with myeloma cells, and hybridoma cell lines that can stably secrete anti-PDCoV S protein specific antibodies are obtained through screening. Subsequently, based on the obtained monoclonal antibody, the preparation of 4H4 single-chain antibody was carried out: total RNA was extracted from 4H4 hybridoma cells, and cDNA was synthesized by reverse transcription using RNA as a template. Then, the heavy chain variable region (VH) and light chain variable region (VL) genes of the monoclonal antibody were amplified by RT-PCR technology. The VH gene and VL gene were linked by a (Gly4Ser) flexible linker peptide to construct the full-length scFv gene. This gene was inserted into the pET-28a prokaryotic expression vector, and the recombinant expression vector was transformed into BL21 competent cells. After induction of expression, separation and purification, dialysis, and refolding, a single-chain antibody specific to PDCoV S CTD protein was obtained. The dialysis and refolding process can restore the native conformation and activity of the single-chain antibody, ensuring its good functional stability. The single-chain antibody can specifically bind to the PDCoV S CTD protein and has good antigen-binding activity. It can be widely used in the specific detection of PDCoV (such as the construction of detection methods such as ELISA and immunofluorescence) and the preparation of related diagnostic reagents.

[0155] While embodiments of the present invention have been described in detail above, it will be apparent to those skilled in the art that various modifications and variations can be made to these embodiments. However, it should be understood that such modifications and variations fall within the scope and spirit of the invention as set forth in the claims. Furthermore, the invention described herein may have other embodiments and can be implemented or carried out in various ways.

Claims

1. A 4H4 positive hybridoma cell line, characterized in that, The 4H4-positive hybridoma cell line has the accession number CCTCC NO:C2026111, is deposited at the China Center for Type Culture Collection on May 20, 2026, and is located at Wuhan University.

2. The application of the 4H4-positive hybridoma cell line as described in claim 1 in the preparation of monoclonal antibodies against PDCoV S CTD protein, characterized in that, The monoclonal antibody was secreted by the 4H4-positive hybridoma cell line.

3. The application of the 4H4-positive hybridoma cell line as described in claim 2 in the preparation of a single-chain antibody against PDCoV S CTD protein, characterized in that, The single-chain antibody was constructed based on the heavy chain variable region and light chain variable region genes of the monoclonal antibody secreted by the 4H4 positive hybridoma cell line.

4. A method for preparing a 4H4-positive hybridoma cell line, used to prepare the 4H4-positive hybridoma cell line as described in claim 1, characterized in that, The preparation method includes: Balb / C mice were immunized four times using purified S-CTD protein truncated variants as immunogens and adjuvants. Monitor the titer of anti-S-CTD protein antibody in mouse serum. Once the titer reaches the preset standard, aseptically obtain mouse spleen cells. Mouse spleen cells were fused with myeloma cells, and 4H4-positive hybridoma cell lines were obtained through screening and clonal culture.

5. The application according to claim 2, characterized in that, The applications include: The 4H4-positive hybridoma cell line was expanded and cultured, and the cell culture supernatant was collected. After separation and purification, monoclonal antibodies were obtained.

6. The application according to claim 3, characterized in that, The applications include: Total RNA was extracted from 4H4-positive hybridoma cell lines and reverse transcribed to synthesize cDNA. Using the cDNA as a template, the heavy chain variable region VH gene and the light chain variable region VL gene were amplified by RT-PCR. A full-length single-chain antibody gene was constructed by linking the VH and VL genes with a flexible linker peptide. The full-length gene of the single-chain antibody was cloned into a prokaryotic expression vector to construct a recombinant expression plasmid. The recombinant expression plasmid was transformed into host cells, and the single-chain antibody was obtained by induction of expression, separation and purification, dialysis and refolding.

7. A single-chain antibody against PDCoV S CTD protein, characterized in that, Its nucleotide sequence is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.

2.

8. The use of a single-chain antibody against the PDCoV S CTD protein as described in claim 7 in the preparation of a kit for detecting or diagnosing PDCoV.